<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>ARTAN Bio (VitaRNA) and Syenex Team Up to Accelerate Next-Generation Anti-Aging Therapy - Hex Index</title>
  <link rel="stylesheet" href="../../styles.css">
</head>
<body class="reading-mode">
  <header class="reading-header">
    <a href="../../index.html" class="back-link">&larr; Back to Library</a>
  </header>
  <main class="reading-content">
    
    <article class="article-page">
      <header class="article-header">
        <h1>ARTAN Bio (VitaRNA) and Syenex Team Up to Accelerate Next-Generation Anti-Aging Therapy</h1>
        <div class="article-meta">
          <span class="author">By VitaDAO</span>
          <span class="separator">&middot;</span>
          <a href="../../publication/vitadao/index.html" class="publication">
            VitaDAO Newsletter
          </a>
          <span class="separator">&middot;</span><time>Jun 26, 2025</time>
          <span class="separator">&middot;</span>
          <span class="read-time">2 min read</span>
        </div>
      </header>

      

      <div class="article-excerpt">
        <div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!9Wu9!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6db03afa-29ce-4dcd-abf6-490fbb7d85e9_1920x1080.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!9Wu9!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6db03afa-29ce-4dcd-abf6-490fbb7d85e9_1920x1080.png 424w, https://substackcdn.com/image/fetch/$s_!9Wu9!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6db03afa-29ce-4dcd-abf6-490fbb7d85e9_1920x1080.png 848w, https://substackcdn.com/image/fetch/$s_!9Wu9!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6db03afa-29ce-4dcd-abf6-490fbb7d85e9_1920x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!9Wu9!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6db03afa-29ce-4dcd-abf6-490fbb7d85e9_1920x1080.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!9Wu9!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6db03afa-29ce-4dcd-abf6-490fbb7d85e9_1920x1080.png" width="1456" height="819" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/6db03afa-29ce-4dcd-abf6-490fbb7d85e9_1920x1080.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:819,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2445281,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://vitadao.substack.com/i/166915834?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6db03afa-29ce-4dcd-abf6-490fbb7d85e9_1920x1080.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!9Wu9!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6db03afa-29ce-4dcd-abf6-490fbb7d85e9_1920x1080.png 424w, https://substackcdn.com/image/fetch/$s_!9Wu9!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6db03afa-29ce-4dcd-abf6-490fbb7d85e9_1920x1080.png 848w, https://substackcdn.com/image/fetch/$s_!9Wu9!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6db03afa-29ce-4dcd-abf6-490fbb7d85e9_1920x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!9Wu9!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6db03afa-29ce-4dcd-abf6-490fbb7d85e9_1920x1080.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"></div></div></div></a></figure></div><p><a href="https://www.artan.bio/">ARTAN Bio</a>(VitaRNA) and <a href="https://www.syenex.com/">Syenex</a> just announced a strategic collaboration that could significantly speed up the development of ARTAN-102, a pioneering gene therapy designed to reverse epigenetic changes associated with aging. This partnership brings together ARTAN's innovative codon suppressor platform with Syenex's VivoCell delivery technology.</p><h2><strong>The Power of Precision Delivery</strong></h2><p>The collaboration centers on a critical challenge in gene therapy: getting the treatment to the right places in the body. Syenex's VivoCell Platform provides the precision in vivo delivery capabilities that ARTAN needs to move their therapy from laboratory proof-of-concept to IND-enabling studies - the crucial step before human trials can begin.</p><p>"<strong>Precise, efficient delivery is critical to maximizing the potential of ARTAN-102,</strong>" explained Dr. Michael Torres, Co-Founder and Chief Scientific Officer of ARTAN Bio. "Syenex's track record in delivery vehicle innovation and manufacturing scale makes them a natural partner as we progress toward IND-enabling studies."</p><h2><strong>What the Partnership Includes</strong></h2><p>The collaboration has three main components:</p><ul><li><p><strong>Rapid Prototyping</strong>: ARTAN gains full access to the VivoCell Platform, including extensive libraries of precision delivery components. Syenex will provide pre-clinical scale prototyping and production support, allowing ARTAN to quickly test and refine delivery approaches.</p></li><li><p><strong>Manufacturing Scale-Up</strong>: Once optimal prototypes are developed, they'll be transferred to Syenex's CDMO (Contract Development and Manufacturing Organization) partners for GMP-grade production - the pharmaceutical quality standard required for clinical trials.</p></li><li><p><strong>Flexible Licensing</strong>: The agreement includes a non-exclusive program license option for the clinical delivery vehicle composition, giving ARTAN strategic flexibility as they move forward.</p></li></ul><h2><strong>About ARTAN-102 and VitaRNA</strong></h2><p>ARTAN Bio, also known as VitaRNA, is developing first-in-class therapeutics designed to restore full-length, functional proteins that become disrupted during aging and age-related disease. Their lead candidate, ARTAN-102, uses a novel codon suppressor approach to address mutations that accumulate as we age, particularly targeting proteins crucial for tumor suppression, DNA repair, and neurological function.</p><p>The VitaRNA project recently released impressive first in vivo data showing ARTAN-102 is safe and reaches multiple tissues in mice. The 14-day study found the therapy successfully reached the liver (350-fold increase), heart (32-fold), lungs (20-fold), brain (4-fold), kidneys (10-fold), and pancreas (12-fold) - all without adverse effects, changes in body weight, or blood cell count alterations.</p><p>Jay Rosanelli, CEO of Syenex, emphasized the potential impact: "ARTAN Bio has generated strong preclinical data on the therapeutic potential of their lead drug candidate, ARTAN-102. By combining their codon suppressor platform with our </p>...</source>
      </div>

      <div class="read-full-article">
        <a href="https://vitadao.substack.com/p/artan-bio-vitarna-and-syenex-team" class="read-button" target="_blank" rel="noopener">
          Read full article on VitaDAO Newsletter &rarr;
        </a>
        <p class="copyright-note">
          This excerpt is provided for preview purposes.
          Full article content is available on the original publication.
        </p>
      </div>
    </article>
  
  </main>
</body>
</html>